logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5439.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5439.produseast1
New tools and approaches to drug-resistant TB | Collections | MSF Science Portal
New tools and approaches to drug-resistant TB

New tools and approaches to drug-resistant TB

The World Health Organization estimates that 410,000 people developed a drug-resistant tuberculosis infection (DR-TB) in 2022, only 40% of whom were diagnosed and started on treatment—and only 63% then cured. Given all these points of failure, innovation in preventing, diagnosing and treating DR-TB cannot come fast enough.

To mark World TB Day (24 March 2024) the content collection linked below highlights recent work by MSF and collaborators to help change this grim picture. The TB-PRACTECAL and endTB studies delivered robust evidence for shorter, safer, more effective drug regimens that are already saving lives worldwide. Other studies explore new approaches to preventive treatment and simpler, quicker, accurate detection of TB and drug resistance—especially among difficult-to-diagnose populations such as children and people living with HIV.

But to impact DR-TB globally these innovations must become widely accessible. This requires changes on many fronts, as described in an accompanying Collection (Expanding Access to Lifesaving New TB Tools).

Collection Content

Journal Article
|
Research

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N,  et al.
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Journal Article
|
Research

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article
|
Research

Detection of Mycobacterium tuberculosis complex using the Xpert MTB/RIF Ultra assay on the stool of pediatric patients in Dushanbe, Tajikistan

Rekart ML, Mun L, Aung A, Gomez D, Mulanda WK,  et al.
2023-01-09 • Microbiology Spectrum
2023-01-09 • Microbiology Spectrum
We report the findings of a prospective laboratory diagnostic accuracy study to evaluate the sensitivity, specificity, and predictive values of the Xpert MTB/RIF Ultra assay for Mycobact...
Conference Material
|
Slide Presentation

Pregnancy outcomes in patients undergoing drug-resistant tuberculosis treatment in two closely monitored cohorts

Lachenal N, Hewison CCH, Berry C, Mitnick CD, Ahmed SM,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
Conference Material
|
Abstract

Can point-of-care ultrasound support tuberculosis diagnosis in children? The experience of MSF in Guinea-Bissau

Moreto-Planas L, Sagrado MJ, Mahajan R, Gallo J, Biague E,  et al.
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION
Tuberculosis (TB) is an important cause of morbidity and mortality in children and over 50% of childhood TB remains undiagnosed every year. As microbiological confirmati...
Journal Article
|
Commentary

Being heard on all-oral therapy for resistant tuberculosis

Furin J, Isaakidis P
2022-05-02 • Lancet Infectious Diseases
2022-05-02 • Lancet Infectious Diseases
Journal Article
|
Research

Feasibility and acceptability of using the novel urine-based FujiLAM test to detect tuberculosis: A multi-country mixed-methods study

Rucker SCM, Lissouba P, Akinyi M, Lubega AV, Stewart RC,  et al.
2022-05-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
2022-05-01 • Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
BACKGROUND
The novel urine-based FujiLAM test identifies tuberculosis in HIV-positive patients but may be challenging to use at point-of-care (POC).

OBJECTIVES
We assess...
Journal Article
|
Research

Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study

Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A,  et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Journal Article
|
Commentary

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic

Mohr-Holland E, Douglas-Jones B, Apolisi I, Ngambu N, Mathee S,  et al.
2021-03-01 • Lancet Child and Adolescent Health
2021-03-01 • Lancet Child and Adolescent Health
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...

See more collections

Diabetes care in humanitarian settings
Diabetes care in humanitarian settings
Diabetes affect hundreds of millions of people worldwide, a large majority of them living in low- and middle-income countries. Yet finding effective strategies, tools and policies for effectively managing this chronic illness—especially amid war, displacement or exclusion from care—is a neglected area of humanitarian medicine. Here we present a cross-section of work on this front by MSF and collaborators. Several studies assess the shift towards community-based, nurse-led models of care in rural settings. Others explore obstacles to diabetes care for war refugees living in camps in Jordan or Lebanon, highlighting how health programs can adapt to their needs. The demonstration that insulin retains potency for 30 days if cooled without refrigeration is opening doors to more patient self-management, as a case study in remote South Sudan shows. At the same time, MSF and others call for regulatory and financing policies that make diabetes medications and supplies cheaper, better adapted to humanitarian settings, and far more available to patients whose lives depend on them.
ASTMH Annual Meeting 2024
ASTMH Annual Meeting 2024

The American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting is an international forum for the exchange of scientific and clinical advances in tropical medicine, hygiene and global health. The scientific content this year is 53% microbe focused, 15% clinically focused, 13% vector focused, 13% globally focused, and 6% intervention focused.

MSF and Epicentre are presenting on access and other challenges for children with visceral and cutaneous leishmaniasis, hurdles in malaria diagnostic testing, and ensuring equitable access to healthcare in conversations about financial sustainability.

This collection features research authored by the presenters and other topics highlighted at ASTMH.

Climate change and health
Climate change and health
The climate crisis is also a health and humanitarian crisis, disproportionately impacting people in the world’s most climate-sensitive regions—mainly low- and low-middle income countries with the least capacity to respond. MSF and other humanitarian organizations witness the consequences daily. More frequent, intense weather events and a warming planet contribute to food and water scarcity, more severe and widespread disease outbreaks, and more injuries and preventable deaths. They also drive massive population displacement, with over 32 million people fleeing their homes in 2022 alone due to floods, drought, storms and fire—nearly triple the number displaced by violence and conflict. As global leaders convene in Dubai for the UN climate conference (COP28, 30 Nov-12 Dec 2023) we present this cross-section of work by MSF and collaborators, drawing from first-hand experience at our medical projects. Emphasizing the urgency of adapting humanitarian operations to the climate crisis, the collection also explores loss and damage through a health lens, proposes policies and practices for creating climate-resilient health organizations, and advocates for embedding fair, just ethics perspectives into humanitarian action and research on climate.
View All Collections